Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
Sarepta Therapeutics soared by 34.98 percent on Wednesday to finish at $23.77 apiece, as investors took path from Morgan Stanley's 25-percent price target upgrade for its stock following strong clinical results from two of its rare disease drug candidates. In a market note, Morgan Stanley raised its price target for Sarepta Therapeutics Inc. (NASDAQ:SRPT) to $25 from $20, while maintaining an “equal weight” rating for the stock. Praxis Precision Medicines, Inc. (PRAX) Gains Analyst Confidence With Ulixacaltamide Photo by Suzy Hazelwood on Pexels The coverage followed the strong results of its SRP-1001 and SRP-1003, in treating patients with facioscapulohumeral muscular dystrophy (FSHD) and myotonic dystrophy type 1, respectively, with results showing a 90 percent reduction of the target protein or mRNA after a single dose, as compared with the 50 to 60 percent range from its competitors. FSHD and DM1 are rare genetic diseases that are caused by othe verexpression of mutant
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Sarepta Therapeutics (SRPT) had its "underperform" rating reaffirmed by Needham & Company LLC.MarketBeat
- Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1Business Wire
- Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 [Yahoo! Finance]Yahoo! Finance
- Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1Business Wire
- Sarepta Therapeutics: A $2B Business Priced Like It's Broken [Seeking Alpha]Seeking Alpha
SRPT
Earnings
- 2/25/26 - Miss
SRPT
Sec Filings
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- SRPT's page on the SEC website